Relevium Technologies Inc. engages in the identification, evaluation, and acquisition of assets or businesses in the health and wellness markets with a focus on e-commerce. The company markets dietary supplements, nutraceuticals, sports nutrition products, and nutri cosmeceuticals primarily through its Bioganix brand portfolio online, as well as dietary supplements under the LeefyLyfe brand name through its wholesale, retail, and online distribution channels. It is also involved in the extraction, formulation, development, and encapsulation of proprietary nutraceutical products for medical purposes. The company was formerly known as BIOflex Technologies Inc. and changed its name to Relevium Technologies Inc. in December 2015. The company was incorporated in 2012 and is headquartered in Montreal, Canada. Relevium Technologies Inc. is a subsidiary of iTech Medical, Inc.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-514-8248559
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$4.09 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Relevium Technologies (CVE:RLV) Frequently Asked Questions
What is Relevium Technologies' stock symbol?
Relevium Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RLV."
Has Relevium Technologies been receiving favorable news coverage?
Media coverage about RLV stock has trended extremely negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Relevium Technologies earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Relevium Technologies.
Who are some of Relevium Technologies' key competitors?
Some companies that are related to Relevium Technologies include Akers Biosciences (AKR), Vigil Health Solutions (VGL), Ambu A/S (AMBBY), ANSELL LTD/S (ANSLY), CONVATEC GRP PL/ADR (CNVVY), Demant A/S (WILLF), Essilor International Cmgn Gnl D Optq (EI), Fisher & Paykel Healthcare (FSPKF), Iris BioTechnologies (IRSB), Lifestyle Delivery Systems (LDS), Lifestyle Delivery Systems (LDSYF), Medigard (MGZ), SECTOR 10 (SECI), STRAUMANN HLDG/ADR (SAUHY) and Straumann (SDMHF).
What other stocks do shareholders of Relevium Technologies own?
Who are Relevium Technologies' key executives?
Relevium Technologies' management team includes the folowing people:
- Mr. Aurelio Useche C.M.A., M.B.A., Pres, CEO & Director (Age 51)
- Mr. Edward Ierfino, Mang. of Investor Relations (Age 51)
- Mr. Wayne D. Cockburn, Consultant (Age 62)
- Mr. Faycal Salek, Chief Financial Officer
- Mr. Abis Hussain, Sr. Marketing Officer
How do I buy shares of Relevium Technologies?
Shares of RLV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Relevium Technologies' stock price today?
One share of RLV stock can currently be purchased for approximately C$0.03.
How big of a company is Relevium Technologies?
What is Relevium Technologies' official website?
How can I contact Relevium Technologies?
Relevium Technologies' mailing address is 1000 Sherbrooke St W Suite 2700, MONTREAL, QC H3A 3G4, Canada. The company can be reached via phone at +1-514-8248559.
MarketBeat Community Rating for Relevium Technologies (CVE RLV)
MarketBeat's community ratings are surveys of what our community members think about Relevium Technologies and other stocks. Vote "Outperform" if you believe RLV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RLV will underperform the S&P 500 over the long term. You may vote once every thirty days.
